Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
or

Annexon Inc (ANNX)

Annexon Inc (ANNX)
2.81 -0.02 (-0.71%) 02/21/25 [NASDAQ]
N/A x N/A N/A x N/A
Realtime by (Cboe BZX)
N/A x N/A N/A x N/A
Realtime 2.81 unch (unch) 02/21/25
Quote Overview for Fri, Feb 21st, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
2.78
Day High
2.93
Open 2.89
Previous Close 2.83 2.83
Volume 578,100 578,100
Avg Vol 1,269,075 1,269,075
Stochastic %K 14.01% 14.01%
Weighted Alpha -66.34 -66.34
5-Day Change -0.20 (-6.64%) -0.20 (-6.64%)
52-Week Range 2.63 - 8.40 2.63 - 8.40
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 299,529
  • Shares Outstanding, K 106,594
  • Annual Sales, $ 0 K
  • Annual Income, $ -134,240 K
  • EBIT $ -132 M
  • EBITDA $ -129 M
  • 60-Month Beta 1.08
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.90

Options Overview Details

View History
  • Implied Volatility 212.63% ( -102.66%)
  • Historical Volatility 69.14%
  • IV Percentile 80%
  • IV Rank 46.52%
  • IV High 445.07% on 02/06/25
  • IV Low 10.42% on 08/13/24
  • Put/Call Vol Ratio 0.01
  • Today's Volume 179
  • Volume Avg (30-Day) 193
  • Put/Call OI Ratio 0.21
  • Today's Open Interest 5,663
  • Open Int (30-Day) 4,334

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.28
  • Number of Estimates 5
  • High Estimate -0.26
  • Low Estimate -0.34
  • Prior Year -0.36
  • Growth Rate Est. (year over year) +22.22%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.63 +6.64%
on 02/19/25
Period Open: 4.17
4.36 -35.54%
on 01/23/25
-1.36 (-32.61%)
since 01/21/25
3-Month
2.63 +6.64%
on 02/19/25
Period Open: 5.17
5.66 -50.35%
on 01/03/25
-2.36 (-45.65%)
since 11/21/24
52-Week
2.63 +6.64%
on 02/19/25
Period Open: 4.91
8.40 -66.55%
on 03/27/24
-2.10 (-42.77%)
since 02/21/24

Most Recent Stories

More News
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

ANNX : 2.81 (-0.71%)
Annexon Announces Presentations Highlighting ANX007 Functional and Structural Differentiation in Geographic Atrophy at the Macula Society 48th Annual Meeting

ANNX : 2.81 (-0.71%)
Annexon Provides 2025 Outlook with Strong Momentum Accelerating into Breakthrough Year

ANNX : 2.81 (-0.71%)
Annexon Expands Board of Directors with Appointment of Commercial Executive William “BJ” Jones

ANNX : 2.81 (-0.71%)
Annexon Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

ANNX : 2.81 (-0.71%)
Annexon, Inc. Reports Positive Real-World Evidence Study Results Supporting ANX005 for Guillain-Barré Syndrome Treatment

Real-world evidence study shows ANX005 improves muscle strength and functional outcomes in Guillain-Barré Syndrome compared to current treatments.Quiver AI SummaryAnnexon, Inc. announced positive topline...

ANNX : 2.81 (-0.71%)
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

ANNX : 2.81 (-0.71%)
Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barré Syndrome (GBS)

ANNX : 2.81 (-0.71%)
Annexon to Present Phase 2 ARCHER Data on Protection of Vision and Photoreceptors with ANX007 in Geographic Atrophy at the Floretina-ICOOR 2024 Meeting

ANNX : 2.81 (-0.71%)
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

ANNX : 2.81 (-0.71%)

Business Summary

Annexon Inc. is a clinical-stage biopharmaceutical company. It engages in developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain and eye. The company's product candidate includes ANX005 and ANX007, which are in clinical stage. Annexon Inc....

See More

Key Turning Points

3rd Resistance Point 3.05
2nd Resistance Point 2.99
1st Resistance Point 2.90
Last Price 2.81
1st Support Level 2.75
2nd Support Level 2.69
3rd Support Level 2.60

See More

52-Week High 8.40
Fibonacci 61.8% 6.20
Fibonacci 50% 5.52
Fibonacci 38.2% 4.84
Last Price 2.81
52-Week Low 2.63

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

Mastering Fibonacci: The Hidden Order in Market Movements